Highland Capital Management continues to expand its strong presence in the healthcare industry in 2017. This past May they closed a private equity fund worth $147 million. The fund is invested in middle market healthcare companies and is anchored by South Korea’s National Pension Service. This will be Highland’s first investment into the Asian healthcare market. This adds to the over $2 billion in other healthcare related assets the company controls. After tripling returns for Highland’s Small Cap Equity Fund in 2016, chief investment officer Michael Gregory suggested they will now be investing in pharmaceutical companies in 2017. He mentioned Collegium Pharmaceuticals and Pacira Pharmaceuticals as potential investments, as they both are developing new pain relieving medications that also work to combat opioid addiction. Back in 2015, the Highland Long/Short Healthcare Fund won the HFM US Hedge Fund Performance award.
Highland is an investment adviser originating from Dallas, Texas, with offices in New York, Sao Paulo, Singapore, and Seoul. James Dondero and Mark Okada founded the company together in 1993 and have since grown it to be worth over $15 billion in investments. They are a global credit manager, handling assets such as hedge funds, alternative investments and distressed securities. Co-Founder Mark Okada also helped to structure some of the first private collateralized loan obligations, known as CLOs. The company represents clients such as corporations, governments, mutual fund investors and even individuals with a high net-worth. The company also invests in philanthropic endeavors focused around their local communities in Texas. Since 2005, they have donated over $10 million to charities.